CD109 Antibody (C-9): sc-271085

CD109 Antibody (C-9) is a mouse monoclonal IgG1 kappa light chain antibody that detects CD109 of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). CD109 (C-9) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CD109 is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein that plays a crucial role in cell signaling and immune response regulation. CD109 expression is particularly notable in CD34+ acute myeloid leukemia cell lines, activated T lymphoblasts, activated platelets, T cell lines, endothelial cells, and various cancers, including lung and esophageal squamous cell carcinomas, as well as testicular tissues. CD109 presence is significant as CD109 is associated with the platelet-specific Gov antigen system, which has implications in platelet transfusion refractoriness, neonatal alloimmune thrombocytopenia, and post-transfusion purpura. Understanding CD109 function is essential, as CD109 is implicated in tumor progression and immune evasion, making CD109 a potential target for therapeutic interventions in cancer treatment.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD109 Antibody (C-9) References:

1. Terminal deoxynucleotidyl transferase activity and B cell markers in chronic myelogenous leukemia blast crisis.  |  Sasaki, R., et al. 1979. Acta Haematol. 62: 143-7. PMID: 118612
2. Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins.  |  Lin, M., et al. 2002. Blood. 99: 1683-91. PMID: 11861284
3. A tyrosine703serine polymorphism of CD109 defines the Gov platelet alloantigens.  |  Schuh, AC., et al. 2002. Blood. 99: 1692-8. PMID: 11861285
4. Antibody W7C5 defines a CD109 epitope expressed on CD34+ and CD34- hematopoietic and mesenchymal stem cell subsets.  |  Giesert, C., et al. 2003. Ann N Y Acad Sci. 996: 227-30. PMID: 12799300
5. CD109 represents a novel branch of the alpha2-macroglobulin/complement gene family.  |  Solomon, KR., et al. 2004. Gene. 327: 171-83. PMID: 14980714
6. CD109 expression in squamous cell carcinoma of the uterine cervix.  |  Zhang, JM., et al. 2005. Pathol Int. 55: 165-9. PMID: 15826242
7. Gova/b alloantigen system on human platelets.  |  Kelton, JG., et al. 1990. Blood. 75: 2172-6. PMID: 2346781
8. CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma.  |  Mo, XT., et al. 2020. Br J Cancer. 123: 833-843. PMID: 32507856
9. Serum CD109 levels reflect the node metastasis status in head and neck squamous cell carcinoma.  |  Hagiwara, S., et al. 2021. Cancer Med. 10: 1335-1346. PMID: 33565282
10. CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer.  |  Adachi, K., et al. 2022. Virchows Arch. 480: 819-829. PMID: 34762199
11. CD109 Is a Critical Determinant of EGFR Expression and Signaling, and Tumorigenicity in Squamous Cell Carcinoma Cells.  |  Zhou, S., et al. 2022. Cancers (Basel). 14: PMID: 35954339
12. CD109 identified in circulating proteomics mitigates postoperative recurrence in chronic rhinosinusitis with nasal polyps by suppressing TGF-β1-induced epithelial-mesenchymal transition.  |  Gao, R., et al. 2024. Int Immunopharmacol. 130: 111793. PMID: 38442581

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CD109 Antibody (C-9) has 26 citations in a variety of scientific publications.

Primary antibodies like Anti-CD109 Antibody (C-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CD109 Antibody (C-9) Specifications

Alternate Product Name: CD109

Product Clone Name: C-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 957-1041

Epitope Target: CD109

Epitope Species: human

Product Reactivity/Detection: CD109

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 26 citations in various scientific publications

Available Conjugates/Forms for CD109 Antibody (C-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin